Head-To-Head Survey: Coherus Oncology (NASDAQ:CHRS) vs. Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics (NASDAQ:CAPR) and Coherus Oncology (NASDAQ:CHRS) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Institutional & Insider Ownership

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by company insiders. Comparatively, 7.2% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Capricor Therapeutics and Coherus Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-56.60%	-43.97%
Coherus Oncology	-259.41%	-222.75%	-52.11%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Capricor Therapeutics and Coherus Oncology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1	6	4	0	2.27
Coherus Oncology	1	0	2	0	2.33

Capricor Therapeutics presently has a consensus price target of $30.25, suggesting a potential upside of 238.37%. Coherus Oncology has a consensus price target of $11.00, suggesting a potential upside of 848.28%. Given Coherus Oncology’s stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Capricor Therapeutics.

Earnings & Valuation

This table compares Capricor Therapeutics and Coherus Oncology”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27 million	23.34	-$105.04 million	($2.45)	-3.65
Coherus Oncology	$42.17 million	4.25	$168.02 million	($1.03)	-1.13

Coherus Oncology has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Capricor Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Summary

Coherus Oncology beats Capricor Therapeutics on 8 of the 14 factors compared between the two stocks.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

About Coherus Oncology

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company’s licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.